Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Intratumoral Avelumab/Ipilimumab Plus CD1c (BDCA-1)+/ CD141 (BDCA-3)+ Myeloid Dendritic Cells in NSCLC Subtitle v3.0: A Randomized Phase II Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Intratumoral Avelumab/Ipilimumab Plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ Myeloid Dendritic Cells in Solid Tumors.

NCT04571632 is registered in ClinicalTrials.gov with Universitair Ziekenhuis Brussel as lead sponsor.

NCT NCT04571632
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04571632 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Intratumoral Avelumab/Ipilimumab Plus CD1c (BDCA-1)+/ CD141 (BDCA-3)+ Myeloid Dendritic Cells in NSCLC Subtitle v3.0: A Randomized Phase II Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Intratumoral Avelumab/Ipilimumab Plus CD1c (BDCA-1)+/CD141 (BDCA-3)+ Myeloid Dendritic Cells in Solid Tumors.
Lead sponsor
Universitair Ziekenhuis Brussel
Phase
Phase 2
Overall status
Unknown status
Start date
September 22, 2020
Completion date
December 31, 2023
Enrollment
36 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer, solid tumor